GlassScriptPhysician profile
Alla Hodges
NPI 1699313916
$12,104.91
in general payments reported to CMS, 2019-2025
40 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,676 · 2022: $2,501 · 2023: $2,606 · 2024: $2,755 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,927.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,007.79 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,022.84 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,400.78 | 2021-2025 | |
| Incyte Corporation | $644.98 | 2022-2024 | Opzelura |
| Pfizer INC. | $619.65 | 2021-2025 | |
| Abbvie INC. | $546.67 | 2022-2025 | |
| Optinose US, INC. | $541.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $373.75 | 2021-2024 | Dupixent |
| Csl Behring | $252.21 | 2021-2024 | Haegarda, Hizentra, Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $240.57 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genentech USA, INC. | $206.91 | 2024 | Xolair |
| Amgen INC. | $206.04 | 2021-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.51 | 2021-2024 | Spiriva Respimat |
| Janssen Biotech, INC. | $136.51 | 2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $131.42 | 2023-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $130.89 | 2021-2024 | Orladeyo |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Indivior INC. | $124.97 | 2025 | Sublocade |
| Kaleo, INC. | $112.84 | 2022-2024 | Auvi-Q |
| Novo Nordisk INC | $106.76 | 2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $99.67 | 2025 | Cologuard Collection Kit |
| Covis Pharma Gmbh | $92.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $91.49 | 2021-2022 | |
| Lilly USA, LLC | $84.10 | 2024-2025 | Zepbound, Mounjaro, Ebglyss |
| Grifols USA, LLC | $75.61 | 2022-2024 | Xembify |
| Antares Pharma, INC. | $72.51 | 2024-2025 | Xyosted |
| Aimmune Therapeutics, INC. | $59.15 | 2021-2025 | Zenpep |
| Blueprint Medicines Corporation | $53.42 | 2023-2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $52.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.23 | 2025 | |
| Phadia US INC. | $50.24 | 2021-2024 | Immunocap |
| Alk-Abello, INC | $49.58 | 2021-2022 | |
| Esperion Therapeutics, INC. | $31.39 | 2025 | Nexletol |
| Protega Pharmaceutials INC | $19.95 | 2025 | Roxybond |
| Galderma Laboratories, L.P. | $18.18 | 2024 | |
| Octapharma USA, INC. | $15.59 | 2023 | Cutaquig |
| Greer Laboratories, INC. | $15.09 | 2024 | Palforzia |
| Vifor Pharma, INC. | $14.81 | 2024 | Zemaira |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | |
| Leo Pharma INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.